Quantum BioPharma

Quantum BioPharma Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM

07/21/2025

🧠 Disrupted neural communication is a key challenge in Multiple Sclerosis.

Lucid-MS, Quantum BioPharma’s investigational therapy, is designed to target demyelination—a core driver of this disruption.

We’re advancing science with a clear focus: restoring the pathways that matter.

Learn More --> https://www.quantumbiopharma.com/lucid-ms

📊 $QNTM |

07/11/2025

🔬 Advancing the Science of Demyelination.

Dedicated to Addressing the Complexities of Neurodegenerative Disease.

Quantum BioPharma Operates with Scientific Integrity at Every Step.

Learn more at:
🌐 www.quantumbiopharma.com

$QNTM

07/08/2025

Quantum BioPharma has submitted its patented MS drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) fast-track program.

Lucid-MS is a first-in-class treatment targeting demyelination in Multiple Sclerosis.

The ILAP submission marks a key step in accelerating regulatory review, clinical development, and patient access in the UK.

https://www.globenewswire.com/news-release/2025/07/08/3111671/0/en/Quantum-BioPharma-Submits-its-Candidate-Breakthrough-Patented-Drug-for-Multiple-Sclerosis-for-Fast-Track-Program-in-the-United-Kingdom.html

$QNTM

07/07/2025

NEWS RECAP JUNE 17th 2025

Quantum BioPharma ($QNTM) and Massachusetts General Hospital (MGH) have officially scanned the first person with Multiple Sclerosis using a next-generation PET-MR imaging tracer—[¹⁸F]3F4AP, Using latest tech GE Signa PET-MR.

This groundbreaking joint study is designed to evaluate a novel PET biomarker that detects myelin damage in the brain and spinal cord with unprecedented clarity. The goal? To transform how MS drug candidates are measured for remyelination and neuroprotection—ushering in a new era of precision imaging in MS research.

🧠 Precision PET imaging
🤝 Leading collaboration with MGH
🔬 Pioneering biomarker science
💊 Supporting future MS therapies

Read the full story:
https://www.globenewswire.com/news-release/2025/06/17/3100574/0/en/Quantum-BioPharma-Announces-First-Person-with-Multiple-Sclerosis-MS-Scanned-in-Joint-Study-with-Massachusetts-General-Hospital.html

$QNTM

07/04/2025

🇺🇸 Happy 4th of July from all of us at Quantum BioPharma! 🇺🇸

06/30/2025

Targeting Demyelination with Novel Science

Lucid-MS is a new chemical entity (NCE) and small molecule drug candidate, developed to address demyelination—a core feature of neurodegenerative diseases like Multiple Sclerosis. The compound is patented and designed for targeted delivery within the central nervous system.

🔬 NCE with differentiated chemistry
🧪 Small molecule
📄 Protected by issued patents

Explore more at: www.quantumbiopharma.com

$QNTM

06/27/2025

🧬 Targeting Demyelination at Its Root.

Quantum BioPharma is a small-cap biotech company focused on demyelination, a core feature of neurodegenerative disease.

Our lead asset is a patented New Chemical Entity, a first-in-class small molecule developed to target the molecular pathways responsible for myelin loss.

This represents more than innovation. It signals a shift in how the scientific community approaches Multiple Sclerosis—as a neurodegenerative disorder requiring new thinking and new tools.

Visit Our Website For More Info:
https://www.quantumbiopharma.com/lucid-ms

$QNTM

Address

Toronto, ON

Telephone

+14168548884

Website

Alerts

Be the first to know and let us send you an email when Quantum BioPharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category